CD6 and ovarian carcinoma: For instance, B3GNT7 and CTSV predicted detrimental prognosis in BRCA2-mut breast cancers, and CD6, CXCL9, and CXCL13 predicted favorable outcomes in BRCA1-mut ovarian cancers.